Table 1.
Clinicobiological characteristics of glioma patients and their corresponding tumors analyzed by both interphase FISH and DNA oligonucleotide expression arrays (n = 40)
Case ID | Histology | WHO grade | Ancestral tumor cell clone | Age | Gender | Karnofsky index (%) | Patient status | Overall survival (months)b |
---|---|---|---|---|---|---|---|---|
1 | Pilocytic astrocytoma | I | Tetraploidy | 21 | F | 80 | Alive | 24 |
2 | Pilocytic astrocytoma | I | Tetraploidy | 50 | F | 90 | Alive | 22 |
3 | Pilocytic astrocytoma | I | +7+10q | 34 | F | 90 | Alive | 10 |
4 | Difuse astrocytoma | II | +7p | 67 | F | 70 | Dead | 11 |
5 | Difuse astrocytoma | II | Tetraploidy | 38 | M | 90 | Alive | 27 |
6 | Anaplastic astrocytoma | III | +7+10q | 30 | M | 80 | Dead | 4 |
7 | Anaplastic astrocytoma | III | Tetraploidy | 27 | M | 90 | Alive | 28 |
8 | GBM | IV | Amp 7p | 67 | F | 60 | Dead | 15 |
9 | GBM | IV | Amp 7p | 50 | F | 80 | Dead | 13 |
10 | GBM | IV | Amp 7p | 71 | F | 60 | Dead | 8 |
11 | GBM | IV | Amp 7p | 70 | M | 80 | Alive | 18 |
12a | GBM | IV | Amp 7p | 70 | F | 70 | Alive | 17 |
13a | GBM | IV | Amp 7p | 45 | F | 60 | Alive | 15 |
14 | GBM | IV | Amp 7p | 48 | M | 90 | Dead | 13 |
15 | GBM | IV | Amp 7p | 74 | M | 60 | Alive | 8 |
16 | GBM | IV | +7 | 69 | F | 60 | Dead | 1 |
17 | GBM | IV | +7 | 79 | M | 80 | Dead | 4 |
18 | GBM | IV | +7 | 62 | M | 60 | Dead | 3 |
19 | GBM | IV | +7 | 67 | M | 60 | Dead | 2 |
20a | GBM | IV | +7q | 70 | F | 80 | Dead | 18 |
21 | GBM | IV | +7q | 35 | F | 80 | Dead | 14 |
22a | GBM | IV | +7q | 39 | F | 80 | Dead | 19 |
23a | GBM | IV | +7p | 30 | F | 80 | Alive | 62 |
24 | GBM | IV | +7p | 69 | M | 60 | Dead | 5 |
25 | GBM | IV | −9p | 67 | F | 70 | Dead | 9 |
26 | GBM | IV | −9p | 50 | F | 50 | Dead | 2 |
27 | GBM | IV | −9p | 73 | M | 70 | Dead | 2 |
28 | GBM | IV | +7p–9p | 66 | M | 80 | Dead | 25 |
29 | GBM | IV | +7p–9p | 74 | M | 70 | Dead | 1 |
30 | GBM | IV | +7p–9p | 84 | M | 70 | Alive | 10 |
31 | GBM | IV | +7p–9p | 56 | M | 80 | Alive | 8 |
32 | GBM | IV | −10q | 76 | F | 60 | Alive | 11 |
33 | GBM | IV | −10q | 60 | M | 60 | Dead | 2 |
34 | Gliosarcoma | IV | +17p+19q | 59 | M | 70 | Dead | 8 |
35a | Gliosarcoma | IV | +7+10q+17p | 39 | M | 80 | Dead | 21 |
36 | OL | II | −1p−19q | 37 | M | 90 | Alive | 11 |
37 | AO | III | −9 | 64 | M | 70 | Dead | 5 |
38 | AO | III | +7p–9p | 53 | M | 70 | Alive | 11 |
39 | Mixed AOA | III | +7–9p | 81 | F | 70 | Dead | 3 |
40a | Mixed AOA | III | −9p | 65 | M | 70 | Alive | 17 |
Abbreviations: FISH, fluorescence in situ hybridization; F, female; M, male; GBM, glioblastoma multiforme; OL, oliodendroglioma; AO, anaplastic oligodendroglioma; AOA, anaplastic oligoastrocytoma.
aRecurrent tumor.
bOverall survival defined from diagnosis to the last visit or date of death.